Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]

  • Awaiting development
  • GID-TA11653
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Lenvatinib + durvalumab + transarterial chemoembolisation + tremelimumab with
chemotherapy within its marketing authorisation for treating advanced hepatocellular
carcinoma